BRIEF published on 09/08/2026 at 07:35, 2 days 18 hours ago GenSight Biologics: Review and Outlook as of September 2026 GenSight Biologics Gene Therapies REVISED STUDY LUMEVOQ® Manufacturing Access Programs
BRIEF published on 09/08/2026 at 07:35, 2 days 18 hours ago GenSight Biologics : Bilan et Perspectives de Septembre 2026 GenSight Biologics Thérapies Géniques Étude REVISE Fabrication LUMEVOQ® Programmes D'accès
PRESS RELEASE published on 09/08/2026 at 07:30, 2 days 18 hours ago Inside Information / Other news releases GenSight Biologics provides business updates on manufacturing, clinical activities, and financial status for September 2026, including progress on gene therapy treatments Financial Updates Manufacturing Business Updates Clinical Activities GenSight Biologics
PRESS RELEASE published on 09/08/2026 at 07:30, 2 days 18 hours ago Informations privilégiées / Autres communiqués GenSight Biologics fait un point sur ses activités de fabrication, cliniques et financières, confirmant la date de publication des comptes semestriels 2026 Fabrication GenSight Biologics Thérapies Géniques Comptes Semestriels Actifs Cliniques
BRIEF published on 07/08/2026 at 19:16, 2 months 2 days ago GenSight Biologics presents its financial situation and therapeutic advances Treasury GenSight Biologics Phase III RECOVER Early Access GS010/LUMEVOQ®
BRIEF published on 07/08/2026 at 19:16, 2 months 2 days ago GenSight Biologics Announces Cash Position and Business Updates Cash Position Clinical Trials Business Updates Early Access Programs Manufacturing Process
BRIEF published on 07/08/2026 at 19:16, 2 months 2 days ago GenSight Biologics annonce sa situation de trésorerie et des mises à jour sur ses activités Essais Cliniques Actualités Commerciales Position De Trésorerie Programmes D'accès Anticipé Processus De Fabrication
BRIEF published on 07/08/2026 at 19:16, 2 months 2 days ago GenSight Biologics présente sa situation financière et ses avancées thérapeutiques Trésorerie GenSight Biologics Phase III RECOVER GS010/LUMEVOQ® Accès Précoce
PRESS RELEASE published on 07/08/2026 at 19:11, 2 months 2 days ago Inside Information / News release on accounts, results GenSight Biologics reports cash position updates as of June 30, 2026, along with business developments, including proceeds from early access programs and manufacturing process improvements Cash Position Business Updates GenSight Biologics Early Access Programs Manufacturing Process
PRESS RELEASE published on 07/08/2026 at 19:11, 2 months 2 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie au 30 juin 2026 et fait un point sur son activité. La trésorerie est de 1,7 million d'euros, encaissant 6,8 millions d'euros au titre de ses programmes d'accès précoce Trésorerie GenSight Biologics Thérapies Géniques Neuropathie Optique Programmes D'accès Précoce
Published on 09/10/2026 at 22:25, 3 hours 28 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 10 hours 33 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 10 hours 53 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/10/2026 at 14:37, 11 hours 16 minutes ago Worksport (NASDAQ:WKSP) Invites Shareholders to September 15 CEO Town Hall
Published on 09/11/2026 at 00:05, 1 hour 48 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/11/2026 at 00:01, 1 hour 52 minutes ago Club Offers for Travel Enthusiasts in Germany
Published on 09/10/2026 at 22:39, 3 hours 13 minutes ago EQS-Adhoc: Notice by Rumble Deutschland AG regarding an upcoming squeeze-out under German Stock Corporation Law
Published on 09/10/2026 at 22:10, 3 hours 42 minutes ago flatexDEGIRO with changes to the Supervisory Board
Published on 09/10/2026 at 22:07, 3 hours 46 minutes ago EQS-Adhoc: flatexDEGIRO SE: Changes to the Supervisory Board
Published on 09/10/2026 at 19:30, 6 hours 23 minutes ago Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 19:30, 6 hours 23 minutes ago Mise à disposition du Rapport Financier Semestriel 2026
Published on 09/10/2026 at 18:10, 7 hours 43 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 août 2026
Published on 09/10/2026 at 17:45, 8 hours 8 minutes ago COGRA : RÉSULTATS ANNUELS 2025/26 - Retour à la croissance rentable et structure financière renforcée
Published on 09/10/2026 at 17:42, 8 hours 10 minutes ago Déclaration d'actions et de droits de vote au 31.08.2026
